ERBB2 and breast cancer: Genomic heterogeneity, identified using next-generation sequencing (NGS), segregates HER2+ BC into at least two major clinically distinct entities: luminal BC and HER2-enriched (HER2E) BC, which have profoundly different gene expression, mostly related to ER signaling [15].